Airway Therapeutics Receives European Medicines Agency Pediatric Committee Approval for Zelpultide Alfa's Study Plan in Bronchopulmonary Dysplasia for Very Preterm Infants

Airway Therapeutics Israel Georgia

Multinational Phase 2b dose selection and Phase 3 expansion study for zelpultide alfa set to begin in late Q3/Q4 2025View original content:https://www.prnewswire.co.uk/news-releases/airway-therapeutics-receives-european-medicines-agency-pediatric-committee-approval-for-zelpultide-alfas-study-plan-in-bronchopulmonary-dysplasia-for-very-preterm-infants-302527017.html